
ROIV Stock Forecast & Price Target
ROIV Analyst Ratings
Bulls say
Roivant Sciences is showing strong financial performance, with a significant increase in total revenue, a consistent decrease in non-GAAP losses per share, and an increase in R&D expenses, all contributing to the company's healthy cash reserves. Additionally, the company's drug candidates, especially IMVT-1402 and Batoclimab, show great potential in their respective markets, making Roivant an attractive investment opportunity.
Bears say
Roivant Sciences is currently overvalued based on a discounted risk-adjusted revenue estimate. With several of its key products still in development, there are significant regulatory, commercial, and technical risks that could impede its success and the valuation. The company's current assets and development plans will need to be closely monitored in order to determine a more accurate valuation.
This aggregate rating is based on analysts' research of Roivant Sciences Ltd and is not a guaranteed prediction by Public.com or investment advice.
ROIV Analyst Forecast & Price Prediction
Start investing in ROIV
Order type
Buy in
Order amount
Est. shares
0 shares